Evidence map›Paper›PMID 40055145›Full record

SynthesisJournal of the American Heart Association2025

Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation in Patients With Cardiogenic Shock: A Systematic Review and Meta-Analysis.

Kyriakos Dimitriadis, Stergios Soulaidopoulos, Nikolaos Pyrpyris, Μarios Sagris, Konstantinos Aznaouridis, Eirini Beneki, Panagiotis Theofilis, Panagiotis Tsioufis, Fotis Tatakis, Christos Fragkoulis and 4 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kyriakos DimitriadisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0003-3186-8905
Stergios SoulaidopoulosFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.
Nikolaos PyrpyrisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0003-0401-9473
Μarios SagrisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0002-3473-1368
Konstantinos AznaouridisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.
Eirini BenekiFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0002-0464-3607
Panagiotis TheofilisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0001-9260-6306
Panagiotis TsioufisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0002-1100-7430
Fotis TatakisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.
Christos FragkoulisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0001-5598-9950
Mony ShuvyJesselson Integrated Heart Centre, Shaare Zedek Medical Center and Faculty of Medicine Hebrew University Jerusalem Israel.
Christina ChrysohoouFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0002-6340-3996
Konstantina AggeliFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.
Konstantinos TsioufisFirst Cardiology Department, Hippokration General Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID 0000-0002-7636-6725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with severe mitral regurgitation and cardiogenic shock demonstrate a poor prognosis. Mitral transcatheter edge-to-edge repair could alter patient management. METHODS AND

resultsWe systematically reviewed PubMed/Medline, Scopus, and Cochrane Library until January 2023, including studies assessing transcatheter edge-to-edge repair in patients with severe mitral regurgitation and cardiogenic shock. Studies with <5 patients were excluded. The primary outcome was device success and all-cause death, while secondary outcomes included myocardial infarction, stroke, and heart failure hospitalization rates at 30-day and intermediate-term follow-up. A fixed-effects meta-analysis was used to estimate pooled rates. Risk of bias was assessed with the Newcastle-Ottawa Scale. A total of 24 studies and 5428 patients were included, with a mean age of 71.2±3.3 years and a high mean Society of Thoracic Surgery score (15.2±8.9). Device success was achieved in 86% (95% CI, 85%-87%) and mitral regurgitation ≤2+ in 89% (95% CI: 88%-90%). The 30-day all-cause mortality rate was 14% (95% CI, 13%-15%). Stroke, myocardial infarction, and heart failure hospitalization rates were 2% (95% CI, 1%-2%), 15% (95% CI, 13%-18%), and 9% (95% CI, 8%-10%), respectively. Patients with acute myocardial infarction had similar device success (81% [95% CI, 74%-87%]), a 30-day mortality rate of 20% (95% CI, 16%-25%), and intermediate-term mortality rate of 14% (95% CI, 9%-19%). In non-myocardial infarction populations, the 30-day mortality rate was 13% (95% CI, 13%-14%), and the intermediate-term mortality rate was 35% (95% CI, 34%-36%).

conclusionsIn patients with mitral regurgitation and cardiogenic shock, transcatheter edge-to-edge repair is associated with favorable 30-day and intermediate-term outcomes. Limitations, including the observational design of included studies and considerable heterogeneity, necessitate further research in this setting.

Indexed as

Cardiac CatheterizationHeart Valve Prosthesis ImplantationMitral ValveMitral Valve InsufficiencyShock, CardiogenicAgedHumansSeverity of Illness IndexTreatment Outcomecardiogenic shockMitraClipmitral regurgitationmyocardial infarctionTEERtranscatheter edge‐to‐edge repair

Identifiers

PMID40055145
PMCPMC12132604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.